Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by
The mRNA Therapeutics Market was valued at USD 11.82 billion in 2023 and is projected to reach USD 48.65 billion by 2032, with a CAGR of 17.04%. The market's growth is driven by mRNA-based vaccines against COVID-19, advancements in mRNA-based cancer therapies, and regulatory approvals. North America leads the market, followed by Europe, while Asia Pacific is expected to grow the fastest.
Sanofi advances a drug for a rare, platelet-destroying disease
Sanofi's rilzabrutinib shows promise in treating immune thrombocytopenia, while Novo Nordisk's etavopivat reduces sickle cell pain crises. Beam Therapeutics' CRISPR therapy for sickle cell yields consistent results, though fertility preservation remains a concern.
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive ...
Rilzabrutinib, a BTK inhibitor, showed significant efficacy in ITP patients, with 65% achieving platelet response vs. 33% on placebo. The study met primary and secondary endpoints, including durable platelet response, reduced bleeding, and improved quality of life. Rilzabrutinib is under regulatory review in the US and EU.
ASH: rilzabrutinib demonstrated significant
Rilzabrutinib, a BTK inhibitor, showed significant efficacy in ITP patients, with 65% achieving platelet response vs. 33% on placebo. The study demonstrated durable platelet response, reduced bleeding, and improved quality of life, positioning rilzabrutinib as a potential first-in-class treatment for ITP.
Rilzabrutinib Demonstrated Significant Patient Benefit in the First Positive Phase 3 Study of a BTK Inhibitor in ITP
Rilzabrutinib, a BTK inhibitor, showed significant efficacy in a Phase 3 study for ITP, achieving platelet response in 65% of patients vs. 33% on placebo. It met primary and secondary endpoints, including durable platelet response, reduced bleeding, and improved quality of life. The safety profile was consistent with previous studies, with mild/moderate AEs like diarrhea and nausea. Rilzabrutinib is under regulatory review in the US and EU.
Animal Biotechnology Market Global Market Projections by 2031
Animal Biotechnology integrates biological sciences and technologies to improve livestock management, disease control, and animal health, addressing global challenges like food security and climate change. The market is set for growth, driven by technological advancements in genomics and rising consumer demand for high-quality animal products. Key players include Bayer AG, Pfizer, Inc., Sanofi, and others, with opportunities for new entrants in precision breeding and vaccines. STATS N DATA's report offers insights into market trends, growth drivers, and regional analysis to 2031.
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple
Indapta Therapeutics collaborates with Sanofi to evaluate allogeneic g-NK cell therapy, IDP-023, combined with Sarclisa in relapsed/refractory multiple myeloma patients. The phase 1 study will explore up to three dose levels of IDP-023 in combination with Sarclisa, with Indapta sponsoring the trial and Sanofi supplying the drug.
Growth CAGR Of 19.3% - AI in Biotechnology Market Size, Share
The Global AI in Biotechnology Market is projected to grow from US$ 4.5 Billion in 2023 to US$ 26.3 Billion by 2033, driven by precision medicine, drug discovery, and personalized healthcare. North America leads with a 40.8% share, and AI technologies like machine learning and natural language processing are transforming biotechnology. Key applications include drug target identification and agriculture biotechnology, with software leading in product types. Partnerships and collaborations are accelerating AI integration in biotechnology.
© Copyright 2024. All Rights Reserved by MedPath